Insight into blood pressure targets for universal coverage of hypertension services in Iran: the 2017 ACC/AHA versus JNC 8 hypertension guidelines

Table 1 Frequency and proportion of participants eligible for pharmacologic and nonpharmacologic therapy*

Type of therapy	%	No.	Sample analysed
Eligible for pharmacologic therapy based on 2017 ACC/AHA
Among samples	37.2 (36.2–38.2)	9746	26,718
Among hypertensive patients	68.2 (66.9–69.5)	9746	14,147
Eligible for pharmacologic therapy based on JNC8
Among samples	28.6 (28.0–29.3)	7805	27,165
Among hypertensive patients	95.7 (95.2–96.1)	7805	8148
Nonpharmacologic therapy
Being overweight or obese	69.4 (68.6–70.2)	11,809	17,028
Insufficient intake of fruits & vegetables (fruits < 2 portions & vegetables < 3 portions)	89.6 (88.9–90.3)	15,527	17,344
Salt Intake > 5 g/day	97.9 (97.6–98.3)	11,718	11,950
Salt Intake > 10 g/day **	42.5 (41.4–43.7)	5208	11,950
Low physical activity (METs < 600/week)	57.2 (56.3–58.2)	8958	15,721
LDL Cholesterol ≥ 130 mg/dL	16.1 (15.3–16.9)	1989	12,248

*Nonpharmacologic therapy is recommended for all individuals with SBP ≥120 mmHg or DBP > 80 mmHg (individuals with elevated, stage 1, and stage 2 hypertension) based on 2017 ACA/AHA
**Since less than 5% of study samples had a salt intake of less than 5 g/day, we considered 10 g/day as the cut-off for the analysis of salt intake

ISSN: 1471-2458